Portfolio

Currus Biologics

Unlocking the power of CAR-T for solid tumours.
Up Arrow Icon

Currus Biologics

→

Leaders
Sam Cobb
Sam Cobb
CEO
Investment Team
challenges
CAR-T cell therapy has been a game changer for blood-based cancers, providing a curative, single-treatment option for the first time in history. Existing treatments for solid tumours have mixed efficacy, so the holy grail is making CAR-T therapy work for solid tumours.
solution
Currus have developed a platform technology that enables any CAR-T therapy to be presented to the immune system such that it will persist and expand in vivo, enabling for the first time, the therapy to infiltrate the hostile solid tumour microenvironment and clear the tumour.
For founders

Building for the systems that matter? Pitch us.

We back founders turning breakthrough science into category-defining companies.

Submit your pitch
For investors

Invest with Main Sequence

Access Australia's deep tech frontier alongside us.

Investor enquiries